Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7403 for:    Anti-Infective Agents AND Antibiotics, Antitubercular AND Anti-Bacterial Agents
Previous Study | Return to List | Next Study

Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit (ProPICU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03440918
Recruitment Status : Completed
First Posted : February 21, 2018
Last Update Posted : June 17, 2019
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Sophie Katz, Vanderbilt University Medical Center

Brief Summary:

The timely use of antibiotics can reduce morbidity and mortality associated with bacterial infections, particularly in the intensive care unit setting (ICU). Long courses of antibiotics, however, are associated with the emergence of multi-drug resistant organisms and antibiotic-associated adverse events, such as C. difficile infections. Thus, antibiotic de-escalation is an important goal of antimicrobial stewardship programs.

Procalcitonin (PCT) has been investigated as a biomarker for critically ill adult patients with bacterial infection, particularly pneumonia and sepsis. The proposed project will evaluate whether a PCT testing and treatment algorithm, implemented through daily antimicrobial stewardship audit and feedback, can promote early and safe antibiotic de-escalation in the pediatric ICU.


Condition or disease Intervention/treatment Phase
Sepsis Procalcitonin Antimicrobial Stewardship Other: Procalcitonin-Guided Antimicrobial Stewardship Other: Baseline Antimicrobial Stewardship Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 271 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Randomized Controlled Trial to Evaluate the Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Actual Study Start Date : February 12, 2018
Actual Primary Completion Date : May 11, 2019
Actual Study Completion Date : May 11, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
Active Comparator: Baseline Antimicrobial Stewardship
Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
Other: Procalcitonin-Guided Antimicrobial Stewardship
In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.

Other: Baseline Antimicrobial Stewardship
Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.

Experimental: Procalcitonin-Guided Antimicrobial Stewardship
In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
Other: Procalcitonin-Guided Antimicrobial Stewardship
In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.




Primary Outcome Measures :
  1. Days of antibiotic therapy in the first 14 days following randomization [ Time Frame: 14 days ]
    Days of antibiotic therapy a participant receives following randomization will be measured


Secondary Outcome Measures :
  1. Duration of broad-spectrum antibiotic therapy [ Time Frame: up to14 days ]
    Defined as vancomycin, daptomycin, amikacin, ceftazidime, cefepime, piperacillin/tazobactam, aztreonam, carbapenems

  2. Time from randomization to first appropriate antibiotic modification [ Time Frame: up to 14 days ]
    Time from randomization to first appropriate antibitoic escalation or de-escalation based on patient's clinical status and available supporting laboratory evidence, or lack thereof, of specific type of infection

  3. 30-day mortality [ Time Frame: up to 30 days ]
    All-cause mortality

  4. Re-initiation of antibiotics for a bacterial infection [ Time Frame: up to 30 days ]
    Re-initiation of any antibiotic for a proven or suspected bacterial infection

  5. Length of intensive care unit stay [ Time Frame: up to 14 days ]
    Hospital days spent in the intensive care unit

  6. Length of overall hospital stay [ Time Frame: Until hospital discharge, an average of 7 days ]
    Hospital days admitted to the hospital

  7. Ventilator days [ Time Frame: up to 14 days ]
    Days spent using invasive ventilation methods (not including supplementary oxygen via nasal cannula or Vapotherm support)

  8. Antibiotic-associated complications [ Time Frame: up to 14 days ]
    Antibiotic-associated complications including rash, neutropenia, thrombocytopenia, acute kidney injury [defined as increase in serum creatinine > 0.3 mg per dL or > 1.5-fold from baseline, or urine output < 0.5 mL per kg per hour for more than six hours], hepatotoxicity [defined as > 2-fold increase in alanine aminotransferase, ALT, or conjugated bilirubin], or C. difficile infection will be recorded

  9. Infection with a multi-drug resistant organism [ Time Frame: up to 30 days ]
    Identification/growth of a multi-drug resistant organism from a sterile culture site. Multi-drug resistant organisms will be defined as methicillin-resistant S. aureus, vancomycin-resistant Enterococcus, 3rd generation cephalosporin non-susceptible Enterobacteriaceae, multi-drug resistant Pseudomonas aeruginosa [resistant to aminoglycosides, cephalosporins, floroquinolones and carbepenems], carbepenem-resistant Acinetobacter, and Candida spp obtained from otherwise sterile sites [i.e. blood or urine cultures]

  10. Antibiotic cost [ Time Frame: up to 14 days ]
    Cost of antibiotic course will be obtained from hospital billing data

  11. Adherence to the procalcitonin-guided algorithm [ Time Frame: up to 5 days ]
    Rate of clinical provider compliance or non-compliance with adherence to suggested antibiotic escalation or de-escalation made by the antimicrobial stewardship team based on procalcitonin levels will be tracked



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or younger
  • Prescribed or administered antibiotics in the hospital less than or equal to 24 hours prior to enrollment
  • Have parents or legal guardians who provide informed consent
  • Provide assent (if > 7 years of age)

Exclusion Criteria:

  • Are not prescribed antibiotics in the hospital
  • Receive intravenous antibiotics within 7 days prior to identification for study enrollment
  • Primary or secondary immune deficiency
  • History of malignancy, bone marrow transplant or solid organ transplant
  • A diagnosis of cystic fibrosis
  • Neonates < 34 weeks gestation
  • Patients receiving treatment for endocarditis, osteomyelitis, meningitis, mediastinitis or other invasive infection, for which long duration of antibiotics is needed
  • Do not provide informed consent/assent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03440918


Locations
Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: Ritu Banerjee, MD, PhD Vanderbilt University Medical Center

Layout table for additonal information
Responsible Party: Sophie Katz, Postdoctoral Fellow, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT03440918     History of Changes
Other Study ID Numbers: 170778
First Posted: February 21, 2018    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sophie Katz, Vanderbilt University Medical Center:
Infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents